Eisai, a Japanese pharmaceutical company, completed the $15m investment in C₂N Diagnostics, an advanced brain health diagnostics company. “The field of highly accurate blood-based diagnostics is rapidly advancing and expanding. Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth. The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer’s disease,” Keisuke Naito, Eisai, Senior Vice President.